Skip to content

PTHS PTHS Amended Sato license — Interest accretion

Similar metrics at other companies

Theravance Biopharma logo
TBPHAmortization And Accretion Income
$602K+84.1%
LQD
LQDAAccretion And Non Cash Interest Expense
$6.49M+39.1%
Popular logo
BPOPNet Accretion Of Discounts Amortization Of Premiums And Deferred Fees
$57.48M-16.5%
Fulton Financial logo
FULTAccretion (Amortization) of Loan Discounts
$10.31M-21.5%
Motorcar Parts of America logo
MPAAAmortization Of Interest On Contract Liabilities
$256K+49.7%
Pilgrim's Pride Corporation logo
PPCAccretion of discount related to Senior Notes
$584K-3.9%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ContractualObligationLiabilityInterestAccretion.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's amended sato license — interest accretion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's amended sato license — interest accretion?
PTHS (PTHS) reported amended sato license — interest accretion of $27K in Q1 2026.
What does amended sato license — interest accretion mean?
This represents the non-cash interest expense recognized over time to adjust the carrying value of the Sato license liability toward its ultimate settlement amount. It reflects the time value of money applied to long-term deferred payment obligations. Higher accretion indicates a larger discount applied to the original liability, impacting the company's non-operating expenses.